Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_2
2
40%
Ph phase_1
3
60%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

completed360%
terminated240%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_2

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT03738423
terminatedphase_2

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT03736967
completedphase_1

Study of REGN3500 and Dupilumab in Patients With Asthma

NCT03112577
completedphase_1

Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma

NCT02999711
completedphase_1

A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects

NCT02958436

Clinical Trials (5)

Showing 5 of 5 trials
NCT03738423Phase 2

Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Terminated
NCT03736967Phase 2

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Terminated
NCT03112577Phase 1

Study of REGN3500 and Dupilumab in Patients With Asthma

Completed
NCT02999711Phase 1

Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma

Completed
NCT02958436Phase 1

A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5